Endotracheally administered antibiotics for gram-negative bronchopneumonia.
Sisomicin or a placebo was administered endotracheally to two groups of 18 and 20 unconscious patients, respectively, who had tracheostomies or endotracheal tubes in place and developed a severe gram-negative broncho-pneumonia. In addition, the patients received systemically a combination of sisomicin and carbenicillin. A favorable clinical response was obtained in 14 (77 percent) of the 18 patients who were treated with sisomicin and in nine (45 percent) of the 20 patients who received the placebo (P less than 0.05). Endotracheal therapy with sisomicin was well tolerated and resulted in high levels of sisomicin and in elevated bactericidal activity within the bronchial secretions. Endotracheally administered amino-glycosides might be an important adjunct to systemically administered antibiotics in the management of severe gram-negative bronchopneumonia.
D001424:Bacterial Infections / Q000188:drug therapy*; D001980:Bronchi / Q000378:metabolism; D001996:Bronchopneumonia / Q000188:drug therapy* / Q000382:microbiology; D002228:Carbenicillin / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy; D005839:Gentamicins / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D007442:Intubation, Intratracheal; D007710:Klebsiella Infections / Q000188:drug therapy; D010919:Placebos; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D012853:Sisomicin / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D014140:Tracheotomy
D005839:Gentamicins; D010919:Placebos; D002228:Carbenicillin; D012853:Sisomicin